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Abstract
Researchers often require customised variations of plasmids that are not commercially available. Here we demonstrate the
applicability and versatility of standard synthetic biological parts (biobricks) to build custom plasmids. For this purpose we
have built a collection of 52 parts that include multiple cloning sites (MCS) and common protein tags, protein reporters and
selection markers, amongst others. Importantly, most of the parts are designed in a format to allow fusions that maintain
the reading frame. We illustrate the collection by building several model contructs, including concatemers of protein
binding-site motifs, and a variety of plasmids for eukaryotic stable cloning and chromosomal insertion. For example, in 3
biobrick iterations, we make a cerulean-reporter plasmid for cloning fluorescent protein fusions. Furthermore, we use the
collection to implement a recombinase-mediated DNA insertion (RMDI), allowing chromosomal site-directed exchange of
genes. By making one recipient stable cell line, many standardised cell lines can subsequently be generated, by fluorescent
fusion-gene exchange. We propose that this biobrick collection may be distributed peer-to-peer as a stand-alone library, in
addition to its distribution through the Registry of Standard Biological Parts (http://partsregistry.org/).
Citation: Constante M, Gru ¨nberg R, Isalan M (2011) A Biobrick Library for Cloning Custom Eukaryotic Plasmids. PLoS ONE 6(8): e23685. doi:10.1371/
journal.pone.0023685
Editor: Jo ¨rg D. Hoheisel, Deutsches Krebsforschungszentrum, Germany
Received April 13, 2011; Accepted July 22, 2011; Published August 25, 2011
Copyright:  2011 Constante et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: MC has a PhD fellowship from the Portuguese Fundac ¸ao para a Cie ˆncia e Tecnologia (FCT). RG has a postdoctoral fellowship from the Human Frontiers
Science Program. MI is funded by the European Research Council, FP7-ERC-201249-ZINC-HUBS, Ministerio de Ciencia e Innovacio ´n grant MICINN BFU2010-17953,
and the MEC-EMBL agreement. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: MI is a PLoS ONE Section Editor (Systems and Synthetic Biology) and has been an Academic Editor since 2006.
* E-mail: marco.constante@crg.es
Introduction
The construction of specific plasmid DNA sequences is a
routine technique in molecular biology laboratories [1]. The most
widely used DNA sequences (for instance, a promoter followed by
a fluorescent protein, a multiple cloning site and a polyadenylation
signal) are easily found in commercially-available plasmids [2,3].
However, when requirements start to become more stringent,
multiple plasmid modifications are required and, although many
changes may be relatively simple to perform, multiple modifica-
tions may become time-consuming cloning challenges.
Complex,multi-factorplasmidshavetobe built frequentlyforthe
applications of synthetic biology [4,5,6], often with the combina-
torial use of different DNA parts [7]. To simplify such types of
constructions an idempotent cloning system has recently been
developed by Tom Knight [8] (described in the BioBrick
Foundation Request for Comments #10, BBF RFC 10; http://
biobricks.org/). Briefly, this system uses a specific set of restriction
enzyme sites at the 39 and 59 ends of each DNA cassette (‘biobrick’),
such that a biobrick ‘A’ may be fused with a biobrick ‘B’ to produce
‘AB’. ‘AB’ contains an uncleavable ‘scar’ sequence between ‘A’ and
‘B’and, importantly,theexactsame setofrestrictionenzyme sitesas
the initial biobricks, at the 39 and 59 ends. In other words, every
biobrickfusionproductisitselfanewbiobrickand mayevenbeused
iteratively for the assembly of concatemers (See Figure 1). Given the
physical idempotent characteristics of the system, biobricks may be
fused together in any combination of parts, with few restrictions in
the number of the biobricks, and no restrictions on the order (‘BA’
would be as simple to construct as ‘AB’).
The RFC 10 Biobrick format [8] is itself very useful and has
formed the core of engineering challenges such as the annual
International Genetically Engineered Machine (iGEM) competi-
tions [9], where students are asked to engineer systems using
biobricks. It is a well-documented system with a large and growing
collection of parts that use the prefix GAATTCGCGGCC-
GCTTCTAGAG (or GAATTCGCGGCCGCTTCTAG for
protein coding parts starting with ATG) and the suffix TAC-
TAGTAGCGGCCGCTGCAG. However, the original scheme
has certain limitations, such as the difficulty of fusing parts coding
for protein domains, since the fusion ‘scar’ changes the codon
reading frame from biobrick ‘A’ to biobrick ‘B’. Phillips and Silver
[10] resolved this issue by presenting a slight modification to the
initial design (removing the last G of the prefix and the first T of
the suffix thereby conserving the reading frame in the scar).
Special attention is required when preparing new parts in this
format (BBF RFC 23), since the removal of the last G of the prefix
means that a Dam methylation site may be formed if the part starts
with TC, which blocks restriction with Xba I. Since the scar
resulting from a RFC 23 fusion (ACTAGA) codes for threonine-
arginine, a chimeric protein ‘AB’ may be assembled from two
RFC 23 biobricks ‘A’ and B’. When preparing such RFC 23
protein fusions, users should be aware that the arginine from the
scar may be problematic since it is positively charged.
It is of interest to note that biobricks in the RFC 23 format may
still be assembled with biobricks in the RFC 10 format without
requiring new restriction enzymes. Although such a RFC 23-RFC
10 cross-fusion does not maintain the 6-bp scar required for the
maintenance of a codon frame, N-terminal fusions of RFC 23
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frameshift is corrected by an adaptor part. In addition, the RFC
23-RFC 10 cross-fusion may be useful for assemblies that do not
require the maintenance of a reading frame or a specific scar size,
such as linking non-coding biobricks (e.g. transcription factor
binding sites). We refer to this compatibility between RFC 23 and
RFC 10 as ‘assembly compatibility’, that should not be confused
with ‘RFC 23 compatibility’ that is reserved for fusion between
biobricks that maintain the reading frame. Further biobrick
formats (with only limited cross-compability) were later proposed
and are documented as BBF RFCs.
Engineering with the Biobrick system is usually accompanied
with an abstraction hierarchy perspective. With this perspective in
mind, one uses ‘DNA’ to design basic ‘parts’ that may then be
assembled into a single functional ‘device’ with a specific function.
Finally, several of these ‘devices’ may be put together to design a
synthetic ‘system’ with a high-level functionality. This hierarchy
facilitates synthetic engineering since, ideally, a researcher
working, for instance, at the ‘system’ level does not need to know
the specific details on how to engineer and build the ‘devices’ used
in that ‘system’.
Synthetic biologists are now in the process of developing and
characterizing basic ‘parts’ or part sets (‘devices’ [11]) that may be
used to engineer biological machines [12,13,14] and to model
them [15]. These parts are available from the Registry of Standard
Biological Parts (http://partsregistry.org/) which is supported by
the BioBricks Foundation (http://bbf.openwetware.org/).
Although the registry is available to any researcher, whether or
not they work in the field of synthetic biology, we believe that the
size of the registry, the existence of different biobrick formats (not
always compatible with each other), and the limited communica-
tion of this resource to non-synthetic biologists, may hamper the
evolution and distribution of biobricks. We therefore developed a
cloning tool that should be of interest outside the field of synthetic
biology; a biobrick toolkit for the construction of custom
eukaryotic expression plasmids, using frequently-used compo-
nents. We originally noted that many biobrick parts that one
would require for eukaryotic projects were apparently missing
Figure 1. The biobrick assembly principle [8,10]. (A) Each biobrick part has the same prefix and suffix, containing restriction enzyme sites. (B)
Following restriction digests, a two-insert ligation into the biobrick vector results in a biobrick fusion. (C) The new biobrick part regenerates the
original prefix and suffix, but contains an in-frame Thr-Arg scar in protein-coding fusions. (D) MS2 binding site concatemers (MS2 BS), built with
iterative biobrick assembly, from 1 to 12-copies (4 steps). M=marker (1 kb ladder). The upstream and downstream sequences between the primer
annealing sites and the biobricks contribute 312 bp, while each MS2 BS is 39 bp.
doi:10.1371/journal.pone.0023685.g001
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sites with different reading frames; an extensive range of reporter
proteins; eukaryotic selection markers; eukaryotic internal ribo-
somal entry sites; and protein epitope tags. Importantly, most of
these parts should be compatible with each other [10,16]. In
addition, the novel use of MCS biobricks facilitates the cloning of
DNA fragments of interest (e.g. open reading frames, promoters),
without having to first remove any internal cleavage sites of the
biobrick enzymes in order to render them ‘biobrick compatible’.
This work is intended to highlight the potential of the biobrick
system to construct custom plasmids for eukaryotic cell lines, for
both synthetic and non-synthetic biologists. Since many parts that
we consider important did not exist in the registry, we have built a
distribution of 9 previously existing and 43 new biobricks. We
demonstrate the utility of the new biobricks with some examples of
assemblies. In addition, we use the created library to establish a
gene-switching system, from tdTomato to EGFP expression, using
recombinase-mediated DNA insertion (RMDI). Finally, we
propose that this collection be distributed peer-to-peer as an
independent library, as well as being available from the registry,
and discuss some advantages in having this type of collection.
Materials and Methods
Preparation of parts
New parts were designed following the recommendations in
BBF RFC 23. Briefly, parts were formatted to contain the prefix
59-GAATTCGCGGCCGCTTCTAGA-39 and the suffix 59-
ACTAGTAGCGGCCGCTGCAG-39. Construction of the parts
was done using 1) oligonucleotide inserts, 2) PCR with
oligonucleotide-directed mutagenesis when required [1] or 3)
synthesized directly by GenScript Corporation (Piscataway, NJ).
Importantly, the part sequences do not start with a TC since this
forms a Dam methylase site (GATC) and digestion with XbaI can
be inhibited. The Biobrick sequences are available at the Registry
of Standard Biological Parts website (http://partsregistry.org/), at
GenBank (http://www.ncbi.nlm.nih.gov/genbank/) and in the
Supporting Information S1.
Biobrick assemblies
Assemblies were performed similarly to the method presented in
the Biobrick assembly kit from New England Biolabs (NEB; Ref.
E0546S) and the Gingko Bioworks manual (http://ginkgobio-
works.com/support/). Alternatively, one may use the adapted
streamlined protocol we have previously reported [14].
Briefly, 500 ng of the upstream part are digested with 20000 U
of EcoRI (NEB) and 10000 U of SpeI (NEB) in NEB EcoRI
buffer. At the same time, 500 ng of the downstream part are
digested with 20000 U of XbaI (NEB) and 20000 U of PstI (NEB)
in NEB Buffer 3. Finally and concomitantly, 500 ng of the
destination plasmid are digested with 20000 U of EcoRI and
20000 U of PstI in NEB EcoRI Buffer. Digestions are performed
at 37uC for 1 hour followed by heat inactivation at 80uC for
20 minutes. Note that the recipient pSB1A* plasmids in the library
contain a ccdB death cassette that is removed in the digestion.
Furthermore, each assembly should contain an antibiotic resis-
tance gene that is not present in either the upstream or the
downstream part (e.g. if the upstream part is in the pSB1AK3
plasmid, containing ampicillin and kanamycin resistance, and the
downstream part is in the pSB1AC3 plasmid, containing
ampicillin and chloramphenicol resistance, the destination plasmid
should be the pSB1AT3 plasmid since it contains the tetracycline
resistance not present in the other plasmids).
Since the destination plasmid contains the ccdB death cassette, a
two-way ligation of the fragments can be done using the Roche
rapid DNA ligation kit, according to the manufacturer’s
instructions, without need for gel isolation or other purifications.
Briefly, 4 ml of the upstream part digestion, 4 ml of the downstream
part digestion and 2 ml of the destination plasmid digestion are
used. 2 ml of the ligation product are transformed in one shot
competent Top10 E. coli (Invitrogen), according to the manufac-
turer’s instructions, and are subsequently plated onto LB agar
plates. The plates contain antibiotic for the resistance provided by
the destination plasmid (in the example above one should use LB
agar plates containing tetracycline) and are incubated overnight.
PCRs of Biobricks (from plasmid DNA or bacterial colony) were
performed using NEB Taq polymerase, using the manufacturer’s
instructions, and using the standard sequencing primers
BBa_G00100 (59-TGCCACCTGACGTCTAAGAA-39) and
BBa_G00101 (59-ATTACCGCCTTTGAGTGAGC-39) with 20
cycles at 55uC annealing temperature, with appropriate denatur-
ation and elongation steps. PCR products were analyzed on
agarose gels and positive colonies were grown overnight for DNA
isolation using the Qiagen spin miniprep kit according to the
manufacturer’s instructions. All clones were verified by DNA
sequencing.
Cell culture and transfection
HEK293 cells were purchased from ATCC. Cells were
propagated in Dulbecco’s Modified Eagle Medium (Gibco)
supplemented with 10% fetal bovine serum (Gibco) and 1%
penicillin-streptomycin (Gibco). Transfection of the cells was
performed with lipofectamine 2000 (Invitrogen), according to the
manufacturer’s instructions, in 6-well plates: cells were incubated
for 4 hours with 4 mg of DNA and 10 ml of lipofectamine reagent.
Stable clones were prepared by selection with 0.5 mg/ml G418
(Sigma).
Cloning small Espin into the MCS of a custom-made
plasmid
Rat small Espin (sEspin) [17] was amplified by PCR, from a
plasmid kindly provided by the group of Herna ´n Lo ´pez-Schier,
using the primers sEspinF (59-AAGAGGGATCCATGAACT-
CCC-39) and sEspinR (59-CTTCTTACCGGTTTACTTAGG-
GATCTCCCCCTTC-39)a t5 5 uC annealing temperature. The
PCR product was cloned into the Biobrick custom plasmid using
the restriction enzymes BamHI and AgeI.
Microscopy
After transfection, cells were allowed to recover overnight and
were dispensed into glass bottom culture dishes (MatTek). 24 h
later, the medium was replaced with PBS for observation under
the microscope.
Recombinase-mediated DNA inclusion plasmid
preparation
The plasmid used for the creation of the stable clone expressing
tdTomato was prepared using an assembly of the biobricks
between the CMV promoter and polyadenylation (pA) signal. The
assembled plasmid was digested with XbaI and PstI and cloned
into pEGFP-C1 digested with NheI and PstI, thereby removing
the EGFP sequence and providing the CMV upstream and pA
downstream of the biobrick insert. Neomycin resistance used for
selection is provided by the pEGFP-C1 plasmid backbone under
the expression of the SV40 early promoter. The EGFP plasmid for
inclusion was prepared using the biobrick collection.
Biobrick Library for Custom Eukaryotic Plasmids
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23685Table 1. List of biobrick parts for eukaryotic plasmids.
Group Nickname Description Registry GenBank
Backbones pSB1A3* High copy number plasmid carrying ampicillin resistance. pSB1A3
pSB1AK3* High copy number plasmid carrying ampicillin and kanamycin resistance. pSB1AK3
pSB1AC3* High copy number plasmid carrying ampicillin and chloramphenicol resistance. pSB1AC3
pSB1AT3* High copy number plasmid carrying ampicillin and tetracyclin resistance. pSB1AT3
Construction Kozak Simple Kozak sequence protein head domain [26] BBa_J96000 JN204869
Stop Tail domain with stop codons in all three frames BBa_J96001 JN204870
CMV* Cytomegalovirus immediate-early promoter BBa_I712004
SV40pA* Eukaryotic – derived from SV40 early poly A signal sequence BBa_J52016
MCS1a Multiple cloning site version 1, first frame BBa_J96002 JN204871
MCS1b Multiple cloning site version 1, second frame BBa_J96003 JN204872
MCS1c Multiple cloning site version 1, third frame BBa_J96004 JN204873
MCS2a Multiple cloning site version 2, first frame BBa_J96005 JN204874
MCS2b Multiple cloning site version 2, second frame BBa_J96006 JN204875
MCS2c Multiple cloning site version 2, third frame BBa_J96007 JN204876
MCS3a Multiple cloning site version 3, first frame BBa_J96008 JN204877
MCS3b Multiple cloning site version 3, second frame BBa_J96009 JN204878
MCS3c Multiple cloning site version 3, third frame BBa_J96010 JN204879
Selection FNeomycin Resistance to G418/neomycin gene [1] BBa_J96011 JN204880
FPuromycin Resistance to puromycin gene [1] BBa_J96012 JN204881
FHSTK Herpes simplex thymidine kinase conferring toxicity to ganciclovir [27] BBa_J96013 JN204882
Reporters tdTomato Engineered red fluorescent protein [28] BBa_J96029 JN204883
EGFP Engineered green fluorescent protein [29] BBa_J96031 JN204884
Cerulean Engineered cyan fluorescent protein [19] BBa_J96032 JN204885
EBFP2 Engineered blue fluorescent protein [30] BBa_J96033 JN204886
mCherry* Engineered red fluorescent protein [28] BBa_J63000
RLuciferase Renilla luciferase gene [31] BBa_J96034 JN204887
Tags Flag FLAG affinity tag [32] BBa_J96035 JN204888
HA HA affinity tag [33] BBa_J96036 JN204889
His His affinity tag [34] BBa_J96037 JN204890
StrepII Strep II affinity tag [35] BBa_J96038 JN204891
Localization SP Membrane or secretion: IgK leader peptide with Kozak [36] BBa_J96014 JN204892
TMD PDGF Receptor Transmembrane Domain [36] BBa_J96015 JN204893
Myristoylation Myristoylation signal sequence with Kozak [37] BBa_J96016 JN204894
NLS* Nuclear Localization Signal from SV40 [38] BBa_J63008
Recombination Loxp Lox p sequence [39] BBa_J96017 JN204895
Lox66 Directional lox sequence compatible with lox71 [40] BBa_J96018 JN204896
Lox71 Directional lox sequence compatible with lox66 [40] BBa_J96019 JN204897
Cistron IRES Internal ribosomal entry site [41] BBa_J96040 JN204898
P2A Self cleaving 2A peptide [42] BBa_J96041 JN204899
T2A Self cleaving 2A peptide [42] BBa_J96042 JN204900
PS3 Short DNA sequence for ribosome recruitment (mini-IRES) [43] BBa_J96043 JN204901
PS4 Short DNA sequence for ribosome recruitment (mini-IRES) [43] BBa_J96044 JN204902
Others Linker 24 aa flexible linker, rich in Gly and Ser. BBa_J96020 JN204903
Spacer1* Randomized DNA spacer BBa_J96021
Spacer2 Randomized DNA spacer BBa_J96022 JN204904
MS2 MS2 phage coat domain binding to RNA at the MS2 binding site sequence [44] BBa_J96023 JN204905
MS2BS MS2 phage coat binding site sequence [44] BBa_J96024 JN204906
LambdaN Lambda N peptide sequence binding to RNA at the boxB binding site [45] BBa_J96025 JN204907
BoxB Lambda N peptide binding site sequence [45] BBa_J96026 JN204908
TEVSite TEV tobacco etch virus protease cleavage site [46] BBa_J96027 JN204909
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Flow-assisted cell sorting (FACS) analysis was performed with
FACSCanto (BD) and cell separation with FACSARIA II (BD).
Results
Library
To create a distribution for the construction of custom plasmids,
we have put together a set of 9 existing and 43 new biobricks and
plasmid backbones. We believe that these should be useful for the
creation of custom-made plasmids for use in eukaryotic cell lines
(see Table 1). Importantly, a set of multiple cloning site (MCS)
biobricks, covering all three different frames has been built,
essential for the combination of the biobrick assembly strategy
with classical cloning strategies (Fig. 2).
To facilitate flexible construction of custom-made plasmids, all
biobricks are in the same format, containing the same prefix and
suffix, as described in the Methods section. Biobricks may be
divided into: (i) Non-coding (not intended for containing coding
sequences; lengths are often not in multiples of three, or have a
stop codons in the sequence). (ii) Head domains (that contain a
Kozak sequence and are used to start the translation of the protein
of interest). (iii) Internal domains (the coding regions for the
desired domains (e.g. reporter proteins). (iv) Tail domains
(containing the stop codon used to stop the translation of the
protein of interest). (v) Translation units (containing the Kozak
sequence, an internal domain and a stop codon). Table 2 indicates
whether a given biobrick maintains the codon frame, whether it
contains a Kozak sequence or a stop codon, and shows the
restriction sites present in each biobrick or plasmid backbone. In
this table we explicitly present those elements that may not be used
for biofusion assembly (highlighted in bold).
Whereas the biobrick assembly workflow will work for all parts
in the collection, for classical cloning it is up to the user to check
which biobricks will be used to assemble a plasmid. For example,
the user must check whether a given restriction enzyme site is
present only once (e.g. in the MCS site region) or whether it is not
unique and is also found in another biobrick or plasmid backbone.
Constructing simple assemblies
The biobrick assembly principle is inherently iterative, allowing
longer and longer poly-biobrick constructs to be built in a stepwise
fashion (Fig. 1). This is particularly useful for making related
constructs with variable copies of a motif, such as a transcription
factor binding sites. To illustrate this, we show how the binding
sites of the bacterial MS2 phage coat protein, which can be used to
repress mRNA translation in synthetic biology applications [18],
can be conveniently concatenated with biobrick assembly (Fig. 1D).
One of the simplest expression plasmids that one might
construct using the distribution is a plasmid such as that presented
in Figure 3A; a simple EGFP expression plasmid, used to label
cells, as may be observed in Figure 3B. A user will typically want to
create a translation unit and insert it under a promoter with a
polyadenylation sequence in the end. The translation unit will
Group Nickname Description Registry GenBank
d1PEST Mouse ornithine decarboxylase PEST sequence 1 hr half-life [47] BBa_96046 JN204910
d2PEST Mouse ornithine decarboxylase PEST sequence 2 hr half-life [47] BBa_96047 JN204911
Asterisks (*) indicate previously existing Biobricks. ‘‘Registry’’ refers to the Registry reference, whereas ‘‘GenBank’’ refers to the GenBank accession number.
doi:10.1371/journal.pone.0023685.t001
Table 1. Cont.
Figure 2. Multiple Cloning Site (MCS) biobricks. The uniqueness of each cloning site is dependent on whether the remaining biobricks and
backbones used for the custom plasmid also contain the restriction site. Blunt end restriction enzymes are represented in italic. These biobricks link
classical cloning to the biobrick system.
doi:10.1371/journal.pone.0023685.g002
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Name Restriction Sites Kozak Stop Backbone Size(bp) 3n Well
Backbones pSB1A3 - - - 2157* - 1A
pSB1AK3 ClaI, HindIII, SmaI, XhoI - - - 3189* - 1B
pSB1AC3 SacI, XhoI - - - 3055* - 1C
pSB1AT3 BamHI, ClaI, HindIII, SalI, SphI, XhoI - - - 3446* - 1D
Construction Kozak YES N AK 12 YES 1E
Stop N YES AK 11 N 1F
CMV SacI N YES AK 654 YES 1G
SV40pA SphI N YES AK 228 YES 1H
MCS1a ApaI, XhoI, BamHI, HindIII N N AK 32 N 2A
MCS1b ApaI, XhoI, BamHI, HindIII N N AT 33 YES 2B
MCS1c ApaI, XhoI, BamHI, HindIII N N AT 34 N 2C
MCS2a BglII, SacI, KpnI, AgeI N N AT 30 YES 2D
MCS2b BglII, SacI, KpnI, AgeI N N AT 31 N 2E
MCS2c BglII, SacI, KpnI, AgeI N N AT 32 N 2F
MCS3a BsrGI, StuI, SalI, SphI, ClaI N N AC 39 YES 2G
MCS3b BsrGI, StuI, SalI, SphI, ClaI N N AC 40 N 2H
MCS3c BsrGI, StuI, SalI, SphI, ClaI N YES AC 41 N 3A
Selection FNeomycin SphI YES YES AK 801 YES 4A
FPuromycin StuI YES YES AC 606 YES 4B
FHSTK ApaI, SmaI, SphI YES YES AC 1137 YES 4C
Reporters tdTomato N N AK 1425 YES 5A
EGFP BsrGI N N AC 714 YES 5B
mCerulean BsrGI, ClaI N N AC 714 YES 5C
EBFP2 N N AC 714 YES 5D
mCherry N N A 705 YES 5E
RLuciferase BsrGI, SphI N N AK 930 YES 5F
Tags Flag N N AC 24 YES 6A
HA N N AC 27 YES 6B
His N N AC 18 YES 6C
StrepII N N AC 24 YES 6D
Localization SP YES N AC 69 YES 7A
TMD N N AC 147 YES 7B
Myrist YES N AC 48 YES 7C
NLS N N A 21 YES 7D
Recombination Loxp N N AC 36 YES 8A
Lox66 N N AC 36 YES 8B
Lox71 N N AC 36 YES 8C
Cistron IRES ApaI, HindIII, KpnI N YES AC 504 YES 9A
P2A SmaI N N AC 42 YES 9B
T2A N N AC 54 YES 9C
PS3 BsrGI N YES AC 50 N 9D
PS4 N YES AC 48 YES 9E
Others Linker N N AC 72 YES 10A
Spacer1 N YES A 72 YES 10B
Spacer2 NNA K 7 0 N1 0 C
MS2 BglII, SacI, SalI N N AK 387 YES 10D
MS2BS SalI N N AC 39 YES 10E
LambdaN N N AC 66 YES 10F
BoxB ApaI N N AC 21 YES 10G
TEVSite N N AC 21 YES 10H
Biobrick Library for Custom Eukaryotic Plasmids
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sequence alone) followed by one or more internal domains (in this
example the EGFP reporter coding sequence) and finished with a
tail domain (here the simple stop codon biobrick).
Constructing a MCS plasmid for classical cloning
Although many commercially-available plasmids contain MCSs
to allow fusing proteins of interest to fluorescent proteins, many
combinations of colours, N-C orientations, stable cell-line selection
genes or half-life modifications are simply not available. To
illustrate this we have created a more complex plasmid, containing
two cistrons, that is not commercially-available. In the first cistron,
we assembled the blue fluorescent protein cerulean [19] before a
complex MCS (assembled using MCS1 and MCS2). We
subsequently cloned an actin-binding protein, rat sEspin [17],
using the BamHI and AgeI restriction sites (Figure 3C). By
fluorescent microscopy, we observed Cerulean-sEspin localization
in actin bundle stress fiber-like structures [17] (Fig. 3D). In the
second cistron we included the neomycin resistance gene for
positive selection. The example shown is just one of many
customized cloning vectors that can be generated with this
platform, and requires just three biobrick cloning iterations (first
round: CMV-Kozak, Cerulean-MCS1a, MCS2a-IRES, Neomy-
cin-pA; second round: CMV-Kozak-Cerulean-MCS1a, MCS2a-
IRES-Neomycin-pA; third round: CMV-Kozak-Cerulean-
MCS1a-MCS2a-IRES-Neomycin-pA). The use of MCSs links
the biobrick format to classical cloning strategies, which should
increase their appeal to researchers who simply wish to ‘cut and
paste’ their DNA cassettes with standard restriction enzymes.
Recombinase-Mediated DNA Insertion
The collection presented here may be used to obtain stable
cloning systems, for chromosomal integration in eukaryotic cells,
such as Recombinase-Mediated DNA Insertion (RMDI) [20]. We
implemented RMDI by establishing a stable cell line expressing
tdTomato, and containing an heteromeric lox site in its coding
sequence (lox66 [21]; see scheme in Figure 4A). Through Cre-
mediated recombination we inserted DNA from a donor plasmid,
containing EGFP preceded by a compatible heteromeric site
(lox71). Thus, red expression was converted to green expression.
Figure 3. Examples of biobrick assemblies. (A) Structure of a classical plasmid for EGFP expression using 5 biobricks. (B) Structure of bicistronic
custom plasmid. 8 biobricks are linked together to make a construct for C-terminal fusions to the blue fluorescent protein, cerulean, using classical
restriction enzyme multiple cloning sites (MCS). For illustration, the actin-bundling binding protein sEspin is cloned into the MCS, resulting in a fusion
with cerulean. (C) Fluorescence microscopy image of the EGFP construct in panel A, after transient transfection into HEK293 cells. (D) A fluorescence
microscopy image of the Cerulean-sEspin fusion construct in panel B, allows the visualisation of stress fiber-like structures in a HEK293T cell. Scale
bars are indicated below each image.
doi:10.1371/journal.pone.0023685.g003
Name Restriction Sites Kozak Stop Backbone Size(bp) 3n Well
d1PEST N YES AT 129 YES 11A
d2PEST N YES AT 129 YES 11B
Characteristics of the collection plasmids. In bold we present all plasmids that, when fused, do not allow for a continuous coding sequence (either because they contain
a stop signal or because the length in bp is not a multiple of 3: ‘‘3n’’). A (ampicillin), C (chloramphenicol), K (kanamycin) and T (tetracycline) indicate the resistances
provided by each backbone. The position of samples in the distribution is indicated by ‘‘Well’’. Asterisks (*) indicate that the presented size refers to the plasmid size
instead of the biobrick size.
doi:10.1371/journal.pone.0023685.t002
Table 2. Cont.
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should express EGFP alone only if inserted at the correct RMDI
site. Expression from random insertions next to genomic
promoters (expected to be rare events) would be associated with
both green and red expression. However, in the early stages after
transfection, even correctly recombined cells would be expected to
have some residual red expression, until the levels of tdTomato
were degraded or diluted by cell division.
Indeed, after three days we observed a cell population
expressing both EGFP and tdTomato by flow cytometry (0.23%
for RMDI when using both the EGFP plasmid and Cre versus
0.08% for random insertion in the control with the EGFP plasmid
without Cre; Fig. 4B and C). Thus, there appeared to be some
Cre-induced increase in GFP fluorescence, but it was not clear
whether the effects were site-specific or due to background
fluorescence. Therefore, to investigate whether the tdTomato
levels would subsequently fall, indicating correct RMDI, we sorted
the EGFP-positive population in Figure 4C, grew them to
confluency and re-analysed the final population. We thus obtained
a population of cells where RMDI had indeed occurred, with high
levels of EGFP and low levels of tdTomato, similar to non-
fluorescent controls (20% green-only cells; Fig. 4D).
When considering only the EGFP-positive population (Q2+Q4)
we note a marked shift in the Q4 population (8% of Q2+Q4
before sorting to 83% of Q2+Q4 after sorting and regrowth). This
suggests that the insertion of the EGFP plasmid occurred at the
intended lox site, thereby disrupting tdTomato, but that extra time
was required for tdTomato levels to fall, via dilution and
degradation, during regrowth of the sorted cells.
The 17% of Q2+Q4 found in Q2 is an EGFP-tdTomato
double-positive population (4% of the total cell population;
Fig. 4D), likely arising from cells containing multiple chromosomal
copies of the initial tdTomato construct: here recombination
occurred in one or more instances, but not in every copy. Random
integrations of GFP near promoter regions are likely to be rare but
may also contribute to this population.
We also observed tdTomato-positive EGFP-negative (32%) and
tdTomato-EGFP double-negative (45%) populations. These are
likely arising from cells that were unmodified and yet were carried-
through the EGFP cell sorting step (false positives) or from cells
that downregulated the CMV promoter [22].
Discussion
In this work, we have created a distribution of DNA fragments
compatible with the Standard Registry of Biological Parts [8]. This
distribution is intended for the specific use of creating custom-
made plasmids, with a focus on use in eukaryotic cell lines,
particularly because many previous parts have focused on
prokaryotic components. We have therefore constructed biobricks
for elements that are routinely used in plasmids for transfection in
eukaryotic cell lines. Using these elements, we provide three
examples of applications of this system: the assembly of sequence
motif concatemers; the assembly of vectors for transient and stable
Figure 4. Recombinase-mediated DNA insertion with biobricks. (A) Schematic view of Cre-mediated recombination between lox66 and
lox71, resulting in the insertion of EGFP and creating a mutated lox site (loxM) and a loxP site. This prevents the original tdTomato from being
expressed while allowing EGFP expression. (B, C and D) Flow cytometry analysis of a stable cell line expressing tdTomato, with various recombinase or
cell sorting treatments. (B) The untreated cell line (2Cre) contains mainly red-positive cells (72%). (C) Upon recombinase treatment (+Cre), the
amount of green cells increases in quadrants 2 and 4 (Q2, Q4). (D) By sorting the green cells (Q2 and Q4 in the previous panel), using flow cytometry
(+Sort), and growing to confluency, the resulting cells are enriched for the newly-generated green cells (20%; Q4).
doi:10.1371/journal.pone.0023685.g004
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Insertion.
Although the present work makes use of existing concepts, such
as the standardization of DNA parts [23] and classical cloning for
expression in eukaryotic cell lines [1], the construction of the
required elements into one collection and the combination of both
cloning concepts makes this method a distinct new resource for
preparing eukaryotic contructs. To provide this tool to users, we
propose that the collection presented here be available as a stand-
alone biobrick distribution exchanged in a peer-to-peer fashion, in
addition to its availability through the Registry of Standard
Biological Parts (http://partsregistry.org/).
A researcher may request access to the Registry to obtain a large
collection of biobricks which are a valuable resource, especially to
synthetic biologists. However, the size of the Registry database
may be detrimental in some instances, especially for sporadic
users. One example of this is the impossibility - at the moment - to
search the registry database for biobricks in a specific format. In
fact, special care must be taken when using biobricks from the
registry since it is not always clear whether two internal protein
domain biobricks may be fused in frame, because of the different
biobrick formats [10,16]. This is in part due to the definition of the
registry database of biobricks as being ‘compatible’ with a given
format when meaning they may be assembled together even if the
coding frame is not maintained, whereas other users may consider
‘compatibility’ as an indication that the fusion conserves the codon
frame.
In contrast, RFC 23 compatibility in the small collection
presented here – in the sense of codon reading frame conservation
– is ensured except where otherwise explicitly stated. Another
advantage of having an independent small distribution for a
specific function is the possibility to exchange it in 96-well plates
and to be sure that one is using sequence-verified components. For
example, when sequence-verifying the registry, certain discrepan-
cies have been found [24]. The bacteria containing the plasmids
can be grown and shipped in wells filled with agar medium,
allowing direct sharing between peers, without need for advanced
robotics or pipetting systems.
We believe that other similar biobrick libraries should be
created to be self-contained. That is, all parts in such libraries
should be compatible and sufficient to be used for a specific
function. For instance one could envisage kinase-phosphatase or
signalling cascade libraries; transcription factor libraries; metabolic
enzyme libraries. Such a library-based form of distribution may be
one of several solutions for the growing size of the Registry that
may rapidly reach a limit in the cost-efficiency of its own
distribution (the registry is .13 000 parts and growing [25]).
Ultimately, we hope to stimulate debate in this growing open
standard for biological engineering.
Supporting Information
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